Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology.

Finberg JP, Rabey JM.

Front Pharmacol. 2016 Oct 18;7:340. eCollection 2016. Review.

2.

EMSAM (deprenyl patch): how a promising antidepressant was underutilized.

Asnis GM, Henderson MA.

Neuropsychiatr Dis Treat. 2014 Oct 6;10:1911-23. doi: 10.2147/NDT.S59107. eCollection 2014. Review. Erratum in: Neuropsychiatr Dis Treat. 2014;10:2069.

3.

Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain.

Fowler JS, Logan J, Volkow ND, Shumay E, McCall-Perez F, Jayne M, Wang GJ, Alexoff DL, Apelskog-Torres K, Hubbard B, Carter P, King P, Fahn S, Gilmor M, Telang F, Shea C, Xu Y, Muench L.

Neuropsychopharmacology. 2015 Feb;40(3):650-7. doi: 10.1038/npp.2014.214. Epub 2014 Sep 24.

4.

Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report.

Kitaichi Y, Inoue T, Mitsui N, Nakagawa S, Kameyama R, Hayashishita Y, Shiga T, Kusumi I, Koyama T.

Neuropsychiatr Dis Treat. 2013;9:1591-4. doi: 10.2147/NDT.S49261. Epub 2013 Oct 17.

5.

Transdermal selegiline for the treatment of major depressive disorder.

Lee KC, Chen JJ.

Neuropsychiatr Dis Treat. 2007;3(5):527-37.

6.

Incomplete response in late-life depression: getting to remission.

Lenze EJ, Sheffrin M, Driscoll HC, Mulsant BH, Pollock BG, Dew MA, Lotrich F, Devlin B, Bies R, Reynolds CF 3rd.

Dialogues Clin Neurosci. 2008;10(4):419-30. Review.

7.

The role of monoamine oxidase inhibitors in current psychiatric practice.

Fiedorowicz JG, Swartz KL.

J Psychiatr Pract. 2004 Jul;10(4):239-48.

8.
9.

Diagnostic and therapeutic advances in treatment-resistant mood disorders.

Blinder BJ, Bloom AR.

West J Med. 1996 Mar;164(3):258-9. No abstract available.

Supplemental Content

Support Center